Guidelines present updated evidence for diagnosing and treating esophageal cancer, indicating significant improvements in patient outcomes with new therapies.
Esophageal cancer represents an aggressive disease positioned as the seventh-leading cause of death from cancer. Esophageal cancer comprises two different diseases that should be distinguished by histology, i.e., squamous cell carcinoma and adenocarcinoma. The epidemiology and molecular differences between these two entities explain their different responsiveness to novel treatments which should be treated independently. The improvement in outcomes of patients with esophageal cancer are obtained when a multidisciplinary therapeutic strategy is utilized. The introduction of targeted therapies including immunotherapy has markedly improved patient outcomes. We present an updated version of the Spanish esophageal cancer guidelines, summarizing the current evidence and available therapies for the treatment of esophageal cancer.
No takes yet. Share an insight, caveat, or question.
Fernandez-Montes et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: